 | Up a level |
Journal Article
Broeckelmann, Paul J., McMullen, Suzanne, Ben Wilson, J., Mueller, Kerstin, Goring, Sarah, Stamatoullas, Aspasia, Zagadailov, Erin, Gautam, Ashish, Huebner, Dirk, Dalal, Mehul and Illidge, Tim (2019). Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br. J. Haematol., 184 (2). S. 202 - 215. HOBOKEN: WILEY. ISSN 1365-2141
Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen, Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2015). Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128 (12). S. 1562 - 1567. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Walewski, Jan 
ORCID: 0000-0003-4247-2674, Hellmann, Andrzej, Siritanaratkul, Noppadol, Ozsan, Guner Hayri, Ozcan, Muhit, Chuncharunee, Suporn, Goh, Ai Sim, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Koren, Jan, Paszkiewicz-Kozik, Ewa, Wang, Bingxia, Singh, Shalini, Huebner, Dirk, Engert, Andreas and von Tresckow, Bastian
(2018).
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Br. J. Haematol., 183 (3).
S. 400 - 411.
HOBOKEN:
WILEY.
ISSN 1365-2141